Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 22-Dec-14 8:07 PM View:  | Siffert Joao Md SVP, R&D | Avanir Pharmaceuticals (AVNR) | 18-Dec-14 | Option Exercise | 32,291 | $2.59 | $83,633.70 | 10% 316.61K to 348.9K | |
| 22-Dec-14 8:07 PM View: | Siffert Joao Md SVP, R&D | Avanir Pharmaceuticals (AVNR) | 18-Dec-14 | Market Option Sale (Planned) | 15,505 | $16.93 | $262,500.00 | (5%) 329.7K to 314.19K | < 1% |
| 18-Dec-14 8:55 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 18-Dec-14 | Market Sale (Planned) | 5,780 | $16.93 | $97,855.40 | (5%) 114.58K to 108.8K | < 1% |
| 22-Dec-14 8:07 PM View: | Siffert Joao Md SVP, R&D | Avanir Pharmaceuticals (AVNR) | 18-Dec-14 | Payment of Exercise | 19,204 | $16.99 | $326,276.00 | (6%) 348.9K to 329.7K | < 1% |
| 18-Dec-14 8:52 AM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 17-Dec-14 | Market Sale (Planned) | 62,520 | $16.93 | $1,058,460.00 | (6%) 976.77K to 914.25K | < 1% |
| 18-Dec-14 8:55 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 16-Dec-14 | Market Option Sale (Planned) | 30,000 | $16.94 | $508,200.00 | (21%) 144.58K to 114.58K | < 1% |
| 18-Dec-14 8:55 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 16-Dec-14 | Option Exercise | 30,000 | $3.52 | $105,525.00 | 26% 114.58K to 144.58K | |
| 18-Dec-14 8:52 AM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 15-Dec-14 | Market Sale (Planned) | 20,000 | $16.95 | $339,000.00 | (2%) 996.77K to 976.77K | < 1% |
| 18-Dec-14 8:52 AM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 15-Dec-14 | Option Exercise | 195,160 | $1.61 | $314,396.00 | 20% 996.77K to 1.19M | |
| 18-Dec-14 8:52 AM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 15-Dec-14 | Market Option Sale (Planned) | 195,160 | $16.95 | $3,307,960.00 | (16%) 1.19M to 996.77K | < 1% |
| 28-Nov-14 9:00 PM View: | Palekar Rohan SVP & Chief Commercial Officer | Avanir Pharmaceuticals (AVNR) | 28-Nov-14 | Market Sale (Planned) | 15,000 | $15.00 | $225,000.00 | (5%) 317.81K to 302.81K | (< 1%) |
| 12-Nov-14 10:00 PM View: | Palekar Rohan SVP & Chief Commercial Officer | Avanir Pharmaceuticals (AVNR) | 10-Nov-14 | Grant | 94,056 | -- | -- | 42% 223.75K to 317.81K | |
| 12-Nov-14 10:00 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 10-Nov-14 | Grant | 51,836 | -- | -- | 83% 62.74K to 114.58K | |
| 12-Nov-14 10:00 PM View: | Siffert Joao Md SVP, R&D | Avanir Pharmaceuticals (AVNR) | 10-Nov-14 | Grant | 94,056 | -- | -- | 19% 504.34K to 598.39K | |
| 12-Nov-14 10:00 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 10-Nov-14 | Grant | 361,174 | -- | -- | 57% 635.6K to 996.77K | |
| 24-Oct-14 8:22 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 24-Oct-14 | Market Sale (Planned) | 2,080 | $11.81 | $24,564.80 | (3%) 79.87K to 77.79K | (< 1%) |
| 24-Oct-14 8:48 PM View: | Siffert Joao Md SVP, R&D | Avanir Pharmaceuticals (AVNR) | 24-Oct-14 | Market Sale (Planned) | 8,426 | $11.80 | $99,426.80 | (4%) 230.98K to 222.55K | (< 1%) |
| 24-Oct-14 8:34 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 24-Oct-14 | Market Sale (Planned) | 27,567 | $11.76 | $324,188.00 | (4%) 760.41K to 732.85K | (< 1%) |
| 17-Sep-14 8:28 PM View: | Palekar Rohan SVP & Chief Commercial Officer | Avanir Pharmaceuticals (AVNR) | 15-Sep-14 | Market Sale (Planned) | 25,000 | $11.50 | $287,500.00 | (9%) 291.75K to 266.75K | < 1% |
| 17-Sep-14 8:44 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 15-Sep-14 | Market Sale (Planned) | 55,000 | $9.45 | $519,750.00 | (41%) 134.87K to 79.87K | (21%) |
| 28-Aug-14 9:03 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 26-Aug-14 | Market Sale (Planned) | 2,110 | $6.10 | $12,871.00 | (3%) 81.98K to 79.87K | (87%) |
| 01-Aug-14 8:44 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 01-Aug-14 | Market Sale (Planned) | 9,670 | $5.26 | $50,864.20 | (1%) 770.08K to 760.41K | (117%) |
| 10-Jul-14 7:42 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 09-Jul-14 | Grant | 20,000 | -- | -- | 3% 750.08K to 770.08K | |
| 30-May-14 8:00 PM View: | Siffert Joao Md SVP, R&D | Avanir Pharmaceuticals (AVNR) | 28-May-14 | Market Sale | 13,547 | $5.18 | $70,173.50 | (6%) 244.53K to 230.98K | (120%) |
| 30-May-14 8:00 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 28-May-14 | Market Sale (Planned) | 442,212 | $5.01 | $2,215,480.00 | (37%) 1.19M to 750.08K | (127%) |
| 16-May-14 8:00 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 16-May-14 | Market Sale | 11,900 | $4.88 | $58,072.00 | (12%) 96.88K to 84.98K | (133%) |
| 16-May-14 8:00 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 14-May-14 | Market Sale | 25,596 | $5.13 | $131,307.00 | (21%) 122.48K to 96.88K | (122%) |
| 14-Feb-14 8:01 PM View: | Wheeler Craig A Director | Avanir Pharmaceuticals (AVNR) | 12-Feb-14 | Grant | 28,900 | -- | -- | 8% 371.49K to 400.39K | |
| 14-Feb-14 7:53 PM View: | Siffert Joao Md SVP, R&D | Avanir Pharmaceuticals (AVNR) | 12-Feb-14 | Grant | 123,750 | -- | -- | 112% 110.23K to 233.98K | |
| 14-Feb-14 7:52 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 12-Feb-14 | Grant | 354,375 | -- | -- | 80% 445.71K to 800.08K | |
| 14-Feb-14 7:59 PM View: | Lyle Corinne H Director | Avanir Pharmaceuticals (AVNR) | 12-Feb-14 | Grant | 21,700 | -- | -- | 37% 58.35K to 80.05K | |
| 14-Feb-14 8:00 PM View: | Podlesak Dennis Director | Avanir Pharmaceuticals (AVNR) | 12-Feb-14 | Grant | 28,900 | -- | -- | 9% 307.49K to 336.39K | |
| 14-Feb-14 7:54 PM View: | Palekar Rohan SVP & Chief Commercial Officer | Avanir Pharmaceuticals (AVNR) | 12-Feb-14 | Grant | 123,750 | -- | -- | 87% 143.0K to 266.75K | |
| 14-Feb-14 7:57 PM View: | Bishop Hans Edgar Director | Avanir Pharmaceuticals (AVNR) | 12-Feb-14 | Grant | 28,900 | -- | -- | 45% 64.45K to 93.35K | |
| 14-Feb-14 7:59 PM View: | Mazzo David J Director | Avanir Pharmaceuticals (AVNR) | 12-Feb-14 | Grant | 28,900 | -- | -- | 9% 307.49K to 336.39K | |
| 14-Feb-14 7:56 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 12-Feb-14 | Grant | 44,375 | -- | -- | 57% 78.1K to 122.48K | |
| 20-Dec-13 5:24 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 18-Dec-13 | Market Sale (Planned) | 29,515 | $2.67 | $78,934.90 | (6%) 475.22K to 445.71K | (326%) |
| 20-Dec-13 5:26 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 18-Dec-13 | Market Sale (Planned) | 2,450 | $2.63 | $6,445.46 | (3%) 80.55K to 78.1K | (333%) |
| 20-Dec-13 5:32 PM View: | Siffert Joao Md SVP, R&D | Avanir Pharmaceuticals (AVNR) | 18-Dec-13 | Market Sale (Planned) | 5,970 | $2.63 | $15,713.00 | (5%) 116.2K to 110.23K | (333%) |
| 19-Dec-13 4:31 PM View: | Palekar Rohan SVP & Chief Commercial Officer | Avanir Pharmaceuticals (AVNR) | 17-Dec-13 | Market Purchase | 10,000 | $2.80 | $28,000.00 | 8% 133.0K to 143.0K | 307% |
| 05-Nov-13 8:01 PM View: | Palekar Rohan SVP & Chief Commercial Officer | Avanir Pharmaceuticals (AVNR) | 04-Nov-13 | Market Purchase | 10,000 | $4.19 | $41,895.00 | 8% 123.0K to 133.0K | 172% |
| 05-Nov-13 8:00 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 01-Nov-13 | Market Sale (Planned) | 4,385 | $4.14 | $18,137.70 | (< 1%) 479.61K to 475.22K | (175%) |
| 19-Sep-13 8:50 PM View: | Siffert Joao Md SVP, R&D | Avanir Pharmaceuticals (AVNR) | 18-Sep-13 | Option Exercise | 21,094 | $1.85 | $39,023.90 | 18% 116.2K to 137.29K | |
| 19-Sep-13 8:50 PM View: | Siffert Joao Md SVP, R&D | Avanir Pharmaceuticals (AVNR) | 18-Sep-13 | Market Option Sale (Planned) | 21,094 | $4.22 | $88,968.20 | (15%) 137.29K to 116.2K | (170%) |
| 02-Aug-13 7:58 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 02-Aug-13 | Market Sale (Planned) | 15,500 | $4.84 | $74,981.20 | (3%) 495.11K to 479.61K | (135%) |
| 17-May-13 8:02 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 15-May-13 | Market Option Sale (Planned) | 215,438 | $3.26 | $702,229.00 | (29%) 745.54K to 530.11K | (249%) |
| 17-May-13 8:01 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 15-May-13 | Market Sale (Planned) | 20,000 | $3.29 | $65,701.30 | (20%) 100.55K to 80.55K | (247%) |
| 17-May-13 8:02 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 15-May-13 | Option Exercise | 215,438 | $0.79 | $170,055.00 | 41% 530.11K to 745.54K | |
| 17-May-13 8:01 PM View: | Ocampo Christine Vice President, Finance | Avanir Pharmaceuticals (AVNR) | 15-May-13 | Option Exercise | 57,700 | $0.88 | $50,776.00 | 57% 100.55K to 158.25K | |
| 17-May-13 8:02 PM View: | Katkin Keith President and CEO Director | Avanir Pharmaceuticals (AVNR) | 15-May-13 | Market Sale (Planned) | 35,000 | $3.26 | $114,084.00 | (7%) 530.11K to 495.11K | (249%) |
